IDegLira for Type 2 Diabetes (REMITiDegLira Trial)

"People aged 30 to 80 who meet the other specified inclusion criteria can apply for this trial. In contrast, there are 227 clinical trials specifically for people under 18 and 1330 research studies for patients over 65."

"IDegLira was first trialled in America, at George Washington University, back in 2002. Since then, a total of 1467 clinical trials have completed. At the moment, there are 218 live studies being conducted; many of these taking place in London and Nova Scotia."

"IDegLira is a medication most commonly used to treat cardiovascular disease, but it can also be given to patients with type 1 diabetes mellitus as well as those looking to improve their liraglutide levels through exercise."

"This clinical study is accepting 159 participants that have type 2 diabetes mellitus and are between 30 and 80 years old."

"IDegLira received a safety score of 3 because there is both efficacy data and multiple rounds of supportive safety data from Phase 3 trials."

"Currently, this trial is open to enrolment at 8 clinics. These locations are situated in London, Ottawa and Hamilton as well as 8 other cities. If you want to make the process of enrolling simpler, choose the clinic nearest to your home."

"Unfortunately, this study has already ended recruitment and is no longer admitting patients. The trial was initially posted on April 23rd, 2019 but was most recently updated on October 19th, 2020. For those still searching for studies, there are currently 1508 trials actively admitting patients with type 2 diabetes mellitus and 218 studies for IDegLira actively searching for patients."

"This study is not enrolling new patients at this time, however that may change in the future as the clinical trial was most recently updated on 10/19/2022. There are 1726 other trials that you might be eligible for if you meet their inclusion criteria."